| Literature DB >> 30511951 |
Mustafa Corum1, Ceyhun Basoglu, Sertac Yakal, Turker Sahinkaya, Cihan Aksoy.
Abstract
OBJECTIVES: To investigate the effects of whole body vibration (WBV) training on isokinetic muscular performance, pain, function, and quality of life in patients with patellofemoral pain (PFP).Entities:
Mesh:
Year: 2018 PMID: 30511951 PMCID: PMC6313045
Source DB: PubMed Journal: J Musculoskelet Neuronal Interact ISSN: 1108-7161 Impact factor: 2.041
Figure 1WBV training position of each exercise. (A) Lunge-step, (B) semi-squat, (C) ball- squeeze squat, and (D) dynamic squat.
Demographic and clinical characteristics of patients.
| WBV group (n = 18) | Control group (n = 16) | ||
|---|---|---|---|
| Mean ± SD or n (%) | P* | ||
| Age (years) | 32.7±7.3 | 33.7±7.7 | 0.694 |
| Weight, kg | 63.1±11 | 63.0±9,8 | 0.977 |
| Height, cm | 161.0±5.7 | 163.0±6.3 | 0.302 |
| BMI (kg/m2) | 24.2±4.2 | 23.5±3.1 | 0.564 |
| Affected extremity, right/left | 8 (44.4) / 10 (55.6) | 10 (55.6) / 6 (37.5) | 0.292 |
| Duration of symptoms | |||
| 3-month - 6-month | 2 (11.1) | 4 (25.0) | 0.391 |
| 6-month - 1-year | 1 (5.6) | 0 (0.0) | |
| >1 year | 15 (83.3) | 12 (75.0) | |
Means (SD) is given for continuous variables; n (%) is given for categorical data. SD, Standard Deviation; BMI, body mass index.
Figure 2Flowchart of study patients.
Analysis of isokinetic performance at measurement intervals in the WBV and control groups.
| Mean ± standard deviation | Within-group comparisons | Between-group comparisons | |||
|---|---|---|---|---|---|
| Outcome measures | Groups | Baseline | Post-treatment | Mean difference (95% CI); P-value | Mean difference (95% CI); P-value; Cohen’s d |
| WBV | 132.3±36.5 | 160.2±28.7 | 27.8 (16.0 to 32.9); <0.001 | 4.1 (-10.5 to 18.8); 0.571; 0.19 | |
| Control | 153.1±31.0 | 176.8±25.9 | 23.7 (14.5 to 39.7); <0.001 | ||
| WBV | 60.3±14.7 | 75.2±14.0 | 14.8 (7.9 to 21.7); <0.001 | 147 (-2.5 to 16.5); 0.147; 0.51 | |
| Control | 71.3±14.5 | 79.1±17.1 | 7.8 (0.7 to 14.9); 0.032 | ||
| WBV | 85.6±21.1 | 106.6±15.8 | 21.0 (12.5 to 29.5); <0.001 | -3.2 (-14.2 to 7.7); 0.551; 0.21 | |
| Control | 96.7±16.6 | 121.0±15.2 | 24.3 (16.7 to 31.8); <0.001 | ||
| WBV | 49.7±16.8 | 64.2±11.9 | 14.4 (8.6 to 20.2); <0.001 | 5.0 (-2.9 to 13.0); 0.205; 0.44 | |
| Control | 55.8±15.0 | 65.2±16.6 | 9.3 (3.4 to 15.3); 0.004 | ||
| WBV | 818.7±246.2 | 965.2±225.8 | 146.4 (44.5 to 248.3); 0.008 | 141.9 (6.3 to 277.5); 0.041 | |
| Control | 965.3±244.1 | 969.8±226.4 | 4.5 (-91.6 to 100.6); 0.922 | ||
| WBV | 771.5±288.9 | 954.6±246.0 | 183.0 (121.2 to 244.8); <0.001 | 86.9 (-12.4 to 186.3); 0.084; 0.60 | |
| Control | 829.7±342.0 | 925.8±358.1 | 96.1 (10.9 to 181.2); 0.029 | ||
| WBV | 66.0±16.2 | 67.0±8.2 | 0.9 (-6.2 to 8.1); 0.785 | 3.6 (-11.7 to 4.4); 0.369; 0.31 | |
| Control | 64.3±8.6 | 68.9±8.5 | 4.5 (0.8 to 8.2); 0.019* | ||
| WBV | 82.3±19.0 | 85.7±15.0 | 3.3 (-4.6 to 11.4); 0.387 | 2.9 (-12.9 to 7.0); 0.555; 0.21 | |
| Control | 76.0±12.1 | 82.3±12.1 | 6.3 (0.0 to 12.5); 0.048 | ||
PT, peak torque; TW, total work; H/Q ratio, hamstring-to-quadriceps ratio; CI, confidence interval.
Paired-samples t test.
ANOVA.
Within- and between-group comparisons of the pain, function and quality of life variables.
| Mean ± standard deviation | Within-group comparisons | Between-group comparisons | ||||
|---|---|---|---|---|---|---|
| Outcome measures | Groups | Baseline | Post- treatment | 6-month follow-up | Mean difference (95% CI); P-value | Mean difference (95% CI); P-value; Cohen’s d |
| VAS (cm) | WBV | 4.9±1.5 | 1.5±1.6 | 2.6±2.5 | a) -3.3 (-4.4 to -2.3); <0.001 | a) -1.8 (-3.0 to -0.6); 0.003 |
| Control | 5.0±1.7 | 3.4±1.9 | 4.0±2.2 | a) -1.5 (-2.6 to -0.4); 0.006 | ||
| KPS | WBV | 81.9±6.2 | 87,5±9.2 | 85.5±11.5 | a) 5.5 (-0.5 to 11.6); 0.080 | a) 2.6 (-5.9 to 11.2); 0.530; 0.21 |
| Control | 70.4±15.7 | 73,3±10.8 | 71.1±14.9 | a) 2.8 (-7.0 to 12.7); 1.000 | ||
| SF-36, PCS | WBV | 50.8±19.1 | 68.7±20.1 | 62.7±20.6 | a) 17.9 (9.2 to 26.7); <0.001 | a) 3.7 (-4.6 to 12.1); 0.374; 0.30 |
| Control | 41.2±13.2 | 55.4±15.4 | 51.5±15.3 | a) 14.2 (7,9 to 20.5); <0.001 | ||
| SF-36, MCS | WBV | 52.8±16.7 | 58.7±17.1 | 61.6±16.3 | a) 5.9 (2.6 to 14.5); 0.252 | a) 2.6 (-5.6 to 11.0); 0.520; 0.22 |
| Control | 47.8±16.0 | 51.1±17.6 | 52.0±17.1 | a) 3.2 (3.0 to 9.6); 0.545 | ||
VAS, visual analog scale; KPS, Kujala Patellofemoral Score; SF-36, Short Form-36; PCS, physical component summary; MCS, mental component summary; CI, confidence interval.
ANOVA.
Figure 3Changes in mean values with standard deviations for visual analog scale, Kujala Patellofemoral Score, Short Form-36 physical component, and Short Form-36 mental component over time in each group. * P<0.05.